share_log

HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

Benzinga ·  Aug 16 19:22  · Ratings

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment